EcoDrugPlus

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSCCRG00000063792
Gene Symbol: CACNA1AB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSCCRG00000026836
Gene Symbol: CACNA2D1A
1 Cross references
228 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSCCRG00000016621
Gene Symbol: CACNA2D1A
1 Cross references
226 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSCCRG00000025699
Gene Symbol: CACNA2D2A
1 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSCCRG00000005696
Gene Symbol: CACNA2D2A
1 Cross references
210 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSCCRG00000034220
Gene Symbol: CACNB1
1 Cross references
207 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSCCRG00000034181
Gene Symbol: CACNB1
1 Cross references
207 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSCCRG00000011606
Gene Symbol: CACNB2A
1 Cross references
200 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSCCRG00000054723
Gene Symbol: CACNB2A
1 Cross references
201 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSCCRG00000028155
Gene Symbol: CACNB3A
1 Cross references
200 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSCCRG00000065887
Gene Symbol: CACNB3A
1 Cross references
200 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 4a Subunit

Ensembl ID : ENSCCRG00000027408
Gene Symbol: CACNB4A
1 Cross references
161 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).